Pharmacokinetics and Pharmacodynamics — MCQs

In isolated intestinal smooth muscle preparations, drug X binds to cholinergic receptors and causes relaxation. In the absence of drug X, acetylcholine binds to the same receptors and causes contraction. At low concentrations of drug X, the efficacy (Emax) of acetylcholine is decreased, but its potency (EC50) remains unchanged. At high concentrations of drug X, acetylcholine has no effect. Which of the following statements about drug X is true?

Q538

What is the percentage of halothane that is metabolized in the human body?

Q539

Which of the following statements about G protein-coupled receptors (GPCRs) is correct?

Q540

Which one of the following drugs has a narrow therapeutic range?

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 531: In the context of drug metabolism, which enzyme system is primarily responsible for the Phase I metabolism of xenobiotics?

A. Cytochrome P-450 (Correct Answer)
B. Glutathione S-transferase
C. NADPH cytochrome P-450-reductase
D. Glucuronyl transferase

Explanation: **Cytochrome P-450** - The **Cytochrome P-450 (CYP450) enzyme system** is a superfamily of enzymes primarily located in the liver that are crucial for Phase I **biotransformation** of xenobiotics. - Phase I reactions, which include **oxidation**, reduction, and hydrolysis, typically introduce or expose a polar functional group on the drug molecule, making it more hydrophilic and often less active. *Glutathione S-transferase* - **Glutathione S-transferases (GSTs)** are involved in **Phase II metabolism**, which involves conjugation reactions to highly polar molecules like glutathione, making compounds more water-soluble for excretion. - They play a key role in the **detoxification** of electrophilic compounds and products of oxidative stress, but not Phase I oxidation. *NADPH cytochrome P-450-reductase* - **NADPH cytochrome P-450 reductase** is an essential enzyme that **supplies electrons** to the cytochrome P-450 enzymes. - While critical for the function of CYP450, it is a **cofactor** or electron donor, not the primary enzyme system responsible for the metabolic reaction itself. *Glucuronyl transferase* - **Glucuronyl transferases (UGTs)** are involved in **Phase II metabolism**, specifically **glucuronidation**, which conjugates a drug or metabolite with glucuronic acid. - This process significantly increases the **water solubility** of the compound, facilitating its elimination from the body.

Question 532: Which of the following drugs is known to cross the blood-brain barrier?

A. Glycopyrrolate
B. Neostigmine
C. Physostigmine (Correct Answer)
D. All of the options

Explanation: ***Physostigmine*** - **Physostigmine** is a **tertiary amine** that is uncharged at physiological pH, allowing it to readily cross the **lipophilic blood-brain barrier**. - Its ability to enter the central nervous system makes it useful for treating **central anticholinergic toxicity**, as it can inhibit acetylcholinesterase in the brain. *Glycopyrrolate* - **Glycopyrrolate** is a **quaternary ammonium compound**, meaning it carries a permanent positive charge. - This charge prevents it from crossing the **blood-brain barrier** effectively, limiting its effects to the peripheral nervous system. *Neostigmine* - **Neostigmine** is also a **quaternary ammonium compound**, similar to glycopyrrolate, making it highly ionized. - Due to its poor lipid solubility and charge, **neostigmine** has very limited penetration into the **central nervous system**. *All of the options* - This option is incorrect because both **glycopyrrolate** and **neostigmine** are charged molecules that do not readily cross the **blood-brain barrier**. - Only **physostigmine** among the listed drugs possesses the necessary lipophilicity to enter the central nervous system.

Question 533: The half-life of oxytocin is

A. 2-3 min
B. 3-5 min (Correct Answer)
C. 5-6 min
D. 7-8 min

Explanation: ***3-5 min*** - The **half-life of oxytocin** is relatively short, typically falling within the range of **3 to 5 minutes** in the human body - This short half-life means that its effects are transient, allowing for **precise control of uterine contractions and milk ejection** - Rapid degradation by **oxytocinases** in the body, particularly during pregnancy, contributes to its quick elimination *2-3 min* - While oxytocin has a short duration of action, 2-3 minutes is generally considered to be slightly shorter than its average half-life - This range underestimates the typical plasma half-life observed in clinical studies *5-6 min* - This range is slightly longer than the commonly accepted half-life for oxytocin - While some variability exists based on factors such as hydration status or renal function, 5-6 minutes exceeds the typical value *7-8 min* - A half-life of 7-8 minutes would be considerably longer than what is observed for endogenous or exogenously administered oxytocin - Such a prolonged half-life would lead to a longer duration of action, which is not characteristic of oxytocin's physiological role

Question 534: Which beta blocker is considered safer for use in patients with hepatic disease?

A. Esmolol (Correct Answer)
B. Betaxolol
C. Bisoprolol
D. Carvedilol

Explanation: **Correct: Esmolol** - **Esmolol** is primarily metabolized by **plasma esterases** (red blood cell esterases), not the liver, making it the safest beta-blocker for patients with **hepatic impairment**. - Its **ultra-short half-life** (approximately 9 minutes) and rapid extrahepatic metabolism minimize drug accumulation and adverse effects in liver disease. - Commonly used in acute settings (ICU, perioperative) where rapid titration is needed. *Incorrect: Betaxolol* - **Betaxolol** is primarily metabolized by the **liver**, and its half-life can be significantly prolonged in patients with hepatic dysfunction. - This increased half-life can lead to **drug accumulation** and an elevated risk of adverse effects such as bradycardia and hypotension. *Incorrect: Bisoprolol* - **Bisoprolol** is eliminated by both **hepatic metabolism** (50%) and **renal excretion** (50%); however, significant liver impairment can still affect its clearance. - While it has a dual elimination pathway providing some safety margin, dose adjustments are often required in severe hepatic dysfunction. *Incorrect: Carvedilol* - **Carvedilol** is extensively metabolized by the **liver**, primarily through CYP2D6 and CYP2C9, leading to significantly altered pharmacokinetics in hepatic disease. - It should be **used with caution in hepatic impairment** due to substantial increase in bioavailability (up to 4-fold) and risk of adverse events including severe hypotension.

Question 535: Which drug has a ceiling effect?

A. Buprenorphine (Correct Answer)
B. Pethidine
C. Morphine
D. Fentanyl

Explanation: ***Buprenorphine*** - Buprenorphine is a **partial opioid agonist**, meaning that it still activates opioid receptors but with a **maximum effect** that is lower than that of full opioid agonists. - Due to its partial agonism, increasing the dose beyond a certain point does not result in a proportional increase in analgesic effect or respiratory depression, demonstrating a **ceiling effect**. *Morphine* - Morphine is a **full opioid agonist** that does not have a ceiling effect for analgesia or respiratory depression. - Its effects continue to increase with increasing doses until severe adverse effects like **respiratory depression** become prohibitive. *Pethidine* - Pethidine (meperidine) is a **full opioid agonist** with no ceiling effect for analgesia or respiratory depression. - Increasing the dose leads to further analgesic effects and an increased risk of **neurotoxicity** due to its metabolite, **normeperidine**. *Fentanyl* - Fentanyl is a potent **full opioid agonist** that also lacks a ceiling effect. - Higher doses rapidly produce greater analgesia and can cause severe, dose-dependent **respiratory depression**.

Question 536: Which of the following statements about Tadalafil is incorrect?

A. Its half life is 17.5 hours
B. It is used in erectile dysfunction
C. It is longest acting phosphodiesterase inhibitor
D. It cannot be used for the treatment of PAH (Correct Answer)

Explanation: ***It cannot be used for the treatment of PAH*** - This statement is incorrect because **Tadalafil** (Adcirca®) is, in fact, approved and commonly used for the treatment of **pulmonary arterial hypertension (PAH)**, as it causes vasodilatation in the pulmonary vasculature. - It works by inhibiting phosphodiesterase-5 (PDE5), leading to increased **cGMP** levels and smooth muscle relaxation in the pulmonary arteries. *It is longest acting phosphodiesterase inhibitor* - This statement is correct. **Tadalafil** has the longest duration of action among the PDE5 inhibitors, with effects lasting up to 36 hours, hence its nickname "the weekend pill." - This extended duration is due to its longer half-life compared to other PDE5 inhibitors like sildenafil or vardenafil. *It is used in erectile dysfunction* - This statement is correct. **Tadalafil** (Cialis®) is widely prescribed for the treatment of **erectile dysfunction (ED)** due to its ability to improve erectile function. - It enhances the effects of nitric oxide, leading to relaxation of penile smooth muscle and increased blood flow necessary for an erection. *Its half life is 17.5 hours* - This statement is correct. The relatively **long half-life of 17.5 hours** is a key pharmacological feature of tadalafil contributing to its prolonged duration of action. - This extended half-life allows for once-daily dosing in some indications and a longer therapeutic window for on-demand use.

Question 537: In isolated intestinal smooth muscle preparations, drug X binds to cholinergic receptors and causes relaxation. In the absence of drug X, acetylcholine binds to the same receptors and causes contraction. At low concentrations of drug X, the efficacy (Emax) of acetylcholine is decreased, but its potency (EC50) remains unchanged. At high concentrations of drug X, acetylcholine has no effect. Which of the following statements about drug X is true?

A. A chemical antagonist
B. A physiologic antagonist
C. Non-competitive antagonist (Correct Answer)
D. Competitive antagonist

Explanation: ***Non-competitive antagonist*** - A non-competitive antagonist binds to a site other than the active site (allosteric site) or irreversibly at the active site, reducing the **maximal effect (Emax)** of the agonist without affecting its potency (EC50) at low concentrations [1] - At **low concentrations** of drug X: Emax of acetylcholine decreases while EC50 remains unchanged - characteristic of non-competitive antagonism [2] - At **high concentrations** of drug X: Acetylcholine is completely ineffective as the antagonist fully blocks receptor function - Drug X causes relaxation while acetylcholine causes contraction, both binding to the same cholinergic receptors, with drug X preventing the conformational change needed for acetylcholine's effect *A chemical antagonist* - A chemical antagonist interacts directly with the **agonist molecule itself** to inactivate it through chemical reaction (e.g., protamine neutralizing heparin), rather than binding to a receptor - This mechanism would reduce the amount of available agonist but would not produce the specific pattern of decreased Emax with unchanged EC50 described in the question - The receptor binding described in the question rules out this mechanism *A physiologic antagonist* - A physiologic antagonist acts on a **different receptor system** to produce an opposing physiological effect (e.g., histamine causing bronchoconstriction vs. epinephrine causing bronchodilation via different receptors) - The question explicitly states that drug X binds to the **same cholinergic receptors** as acetylcholine, eliminating physiologic antagonism as the mechanism - Both drugs compete for the same receptor site rather than acting through separate pathways *Competitive antagonist* - A competitive antagonist binds **reversibly** to the same receptor site as the agonist, competing for binding in a concentration-dependent manner [2] - This would **increase EC50** (shift dose-response curve to the right, decreasing potency) while maintaining the **same Emax** if sufficient agonist is added to outcompete the antagonist [1] - The question shows the opposite pattern: **decreased Emax with unchanged EC50**, which is incompatible with competitive antagonism

Question 538: What is the percentage of halothane that is metabolized in the human body?

A. 50%
B. 5%
C. 2.50%
D. 25% (Correct Answer)

Explanation: **Correct: 25%** - Approximately **25%** of administered halothane is metabolized in the liver, which is a relatively high percentage compared to other volatile anesthetics. - This extensive metabolism can lead to the formation of reactive intermediates, contributing to its potential for **hepatotoxicity** (halothane hepatitis). *Incorrect: 50%* - **50%** metabolism is significantly higher than what is observed for halothane and would imply even greater risk of significant metabolic byproduct accumulation and toxicity. - Most volatile anesthetics are metabolized to a much lesser extent, with desflurane having the least metabolism (<0.02%). *Incorrect: 5%* - **5%** metabolism is too low for halothane; while some volatile anesthetics like isoflurane fall into this range (~0.2-2%), halothane is known for its considerably higher metabolic rate. - A 5% metabolism rate would result in less concern for and incidence of **halothane hepatitis**. *Incorrect: 2.50%* - **2.50%** metabolism is an underestimation of halothane's metabolic activity within the body. - Anesthetic agents such as **enflurane** have a metabolism rate closer to this value (~2-5%), whereas halothane is much higher.

Question 539: Which of the following statements about G protein-coupled receptors (GPCRs) is correct?

A. The alpha subunit of G proteins determines whether they are stimulatory or inhibitory. (Correct Answer)
B. G proteins bind hormones directly before transmitting signals to receptors.
C. G proteins are active when bound to GDP and inactive when bound to GTP.
D. G proteins require the beta and gamma subunits to remain bound to the alpha subunit to transmit signals.

Explanation: ***The alpha subunit of G proteins determines whether they are stimulatory or inhibitory.*** - The **alpha subunit** of a G protein determines its specific function, such as activating or inhibiting downstream enzymes like adenylyl cyclase, thereby classifying the G protein as Gs (stimulatory), Gi (inhibitory), or Gq. - This specificity arises from the **alpha subunit's unique binding sites** for downstream effectors and its intrinsic GTPase activity, which regulates its activation state. *G proteins require the beta and gamma subunits to remain bound to the alpha subunit to transmit signals.* - This is **incorrect**. Upon activation, the **alpha subunit dissociates from the beta-gamma dimer**, and both components function **independently** to modulate downstream effectors. - The **alpha subunit** regulates enzymes like adenylyl cyclase or phospholipase C, while the **beta-gamma complex** can independently modulate ion channels and other effector proteins. *G proteins bind hormones directly before transmitting signals to receptors.* - **G protein-coupled receptors (GPCRs)** are responsible for binding hormones (ligands) directly, which then causes a **conformational change in the receptor**. - This conformational change is what then activates the associated G protein, which subsequently transmits the signal to intracellular effectors. *G proteins are active when bound to GDP and inactive when bound to GTP.* - **G proteins are generally active when bound to GTP** and inactive when bound to GDP. - Upon activation, the G protein exchanges GDP for GTP, which leads to its conformational change and dissociation into active alpha and beta-gamma subunits.

Question 540: Which one of the following drugs has a narrow therapeutic range?

A. Propranolol
B. Phenytoin (Correct Answer)
C. Piroxicam
D. Prazosin

Explanation: ***Phenytoin*** - **Phenytoin** has a **narrow therapeutic index**, meaning there is a small difference between the therapeutic and toxic doses. - This necessitates **therapeutic drug monitoring** to ensure effective treatment while avoiding adverse effects like nystagmus, ataxia, or gingival hyperplasia. *Propranolol* - **Propranolol** is a **beta-blocker** used for hypertension, angina, and arrhythmias, generally considered to have a wide therapeutic range. - While dose adjustments are common, routine therapeutic drug monitoring is typically **not required** due to its relatively safe profile at higher doses compared to drugs like phenytoin. *Piroxicam* - **Piroxicam** is a **nonsteroidal anti-inflammatory drug (NSAID)** with a relatively wide therapeutic window. - Its primary concerns are gastrointestinal and renal side effects rather than toxicity from a narrow therapeutic range. *Prazosin* - **Prazosin** is an **alpha-1 adrenergic blocker** used for hypertension and benign prostatic hyperplasia, and it generally has a wide therapeutic range. - The main concern with prazosin is **first-dose phenomenon** (orthostatic hypotension), which is an initial effect rather than toxicity from a narrow therapeutic window.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free